Literature DB >> 16150576

Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.

Vicente Molina1, Santiago Reig, Javier Sanz, Tomás Palomo, Carlos Benito, Javier Sánchez, Fernando Sarramea, Javier Pascau, Manuel Desco.   

Abstract

The effects of atypical antipsychotic treatment on the brain volume deficits associated with schizophrenia are poorly understood. We assessed the brain volumes of eleven healthy controls and 29 patients with schizophrenia, using magnetic resonance imaging at baseline and at follow-up after two years of treatment with atypical neuroleptics. Two groups of patients were analyzed: treatment-naïve patients (n = 17) and chronic treatment-resistant patients (n = 12). Treatment-naïve patients received risperidone during the follow-up period, whereas chronic patients received clozapine. Gray matter (GM) and white matter (WM) volumes in the frontal, parietal, occipital, and temporal lobes were measured. Contrary to the controls, both groups of patients presented GM increases and WM decreases in the parietal and occipital lobes (p < .005). Frontal GM also increased in the chronic group with clozapine. There was a significant (p < .001) inverse relationship between the baseline volumes (GM deficit/WM excess) and the longitudinal change. These GM and WM changes were not related to changes in weight. Thus, treatment with risperidone and clozapine in schizophrenia may have an effect on gray and white matter volume and needs further exploration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150576     DOI: 10.1016/j.schres.2005.07.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  37 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 3.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

4.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

5.  Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment.

Authors:  Mohamed Ahmed; Dara M Cannon; Cathy Scanlon; Laurena Holleran; Heike Schmidt; John McFarland; Camilla Langan; Peter McCarthy; Gareth J Barker; Brian Hallahan; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2015-04-01       Impact factor: 7.853

6.  White Matter in Schizophrenia Treatment Resistance.

Authors:  Peter Kochunov; Junchao Huang; Song Chen; Yanli Li; Shuping Tan; Fengmei Fan; Wei Feng; Yunhui Wang; Laura M Rowland; Anya Savransky; Xiaoming Du; Joshua Chiappelli; Shuo Chen; Neda Jahanshad; Paul M Thompson; Meghann C Ryan; Bhim Adhikari; Hemalatha Sampath; Yimin Cui; Zhiren Wang; Fude Yang; Yunlong Tan; L Elliot Hong
Journal:  Am J Psychiatry       Date:  2019-07-29       Impact factor: 18.112

7.  White matter changes associated with antipsychotic treatment in first-episode psychosis.

Authors:  Philip R Szeszko; Delbert G Robinson; Toshikazu Ikuta; Bart D Peters; Juan A Gallego; John Kane; Anil K Malhotra
Journal:  Neuropsychopharmacology       Date:  2013-10-16       Impact factor: 7.853

8.  In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.

Authors:  George Bartzokis; Po H Lu; Stephanie B Stewart; Bolanle Oluwadara; Andrew J Lucas; Joanna Pantages; Erika Pratt; Jonathan E Sherin; Lori L Altshuler; Jim Mintz; Michael J Gitlin; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-17       Impact factor: 4.939

9.  Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss.

Authors:  Gary Price; Mara Cercignani; Elvina M Chu; Thomas R E Barnes; Gareth J Barker; Eileen M Joyce; Maria A Ron
Journal:  Neuroimage       Date:  2009-07-23       Impact factor: 6.556

10.  White matter microstructure in schizophrenia: effects of disorder, duration and medication.

Authors:  Richard Kanaan; Gareth Barker; Michael Brammer; Vincent Giampietro; Sukhwinder Shergill; James Woolley; Marco Picchioni; Timothea Toulopoulou; Philip McGuire
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.